UnknownNCT03075969
Phase IV EORTC Quality of Life Module for Patients With Chronic Myeloid Leukemia
Studying Chronic myeloid leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
- Principal Investigator
- Fabio Efficace, PhDGIMEMA Foundation
- Enrollment
- 337 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2017 – 2019
Study locations (30)
- Winship Cancer Institute of Emory University, Emory, Georgia, United States
- Innsbruck Medical University, Innsbruck, Austria
- Complexo Hospital de Clinicas da Universidade Federal do Parana, Paranã, Brazil
- Guangdong Medical University, Guangdong, China
- Universität Heidelberg, Heidelberg, Germany
- Baghdad Teaching Hospital, Baghdad, Iraq
- Azienda Ospedaliero - Universitaria Ospedali Riuniti Umberto I - G.M. Lancisi - G. Salesi, Ancona, Italy
- Azienda Ospedaliero-Universitaria Policlinico Consorziale, Bari, Italy
- Department of Oncology and Hematology, O.U. of Hematology, S. Orsola-Malpighi University Hospital, Bologna, Bologna, Italy
- Sezione di Ematologia e Trapianti Spedali Civili, Brescia, Italy
- CTMO - Ematologia - Ospedale Binaghi, Cagliari, Italy
- Divisione clinicizzata di Ematologia - Dipartimento di Scienze Mediche - Osp. Ferrarotto, Catania, Italy
- Clinica Ematologica - Dipartimento di Medicina Interna - IRCCS San Martino - IST, Genova, Italy
- Lecce ASL Le/1 P.O. Vito Fazzi - U.O. di Ematologia ed UTIE, Lecce, Italy
- U.O. Ematologia 1 - Centro Trapianti di Midollo - Ospedale Maggiore Milano, Milan, Italy
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03075969 on ClinicalTrials.govOther trials for Chronic myeloid leukemia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07354074Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CPNovartis Pharmaceuticals
- RECRUITINGNCT07375355Real-world Study of Scemblix in the Treatment of Chronic Myeloid Leukemia in ChinaNovartis Pharmaceuticals
- ENROLLING BY INVITATIONNCT07383298Observational Study on Dose Optimization of Olverembatinib in Patients With Chronic Myeloid Leukemia in Chronic or Accelerated PhaseQian Jiang
- RECRUITINGPHASE2NCT06817720Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic PhaseM.D. Anderson Cancer Center
- RECRUITINGNCT07061145A Potential Relationship Between Treatment With Tyrosine Kinase Inhibitors and Erectile Dysfunction in Male Patients With Chronic Myeloid LeukemiaAzienda USL Reggio Emilia - IRCCS
- RECRUITINGPHASE2NCT06409936PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CMLGruppo Italiano Malattie EMatologiche dell'Adulto
- RECRUITINGPHASE2NCT06514534Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligible to Ponatinib.Novartis Pharmaceuticals
- RECRUITINGPHASE1NCT06787144ELVN-001 for the Treatment of Chronic Myeloid Leukemia With and Without T315I Mutation in Japanese ParticipantsEnliven Therapeutics